Evaluation of ZAR1 and SFRP4 methylation status as potentials biomarkers for diagnosis in cervical cancer: exploratory study phase I

Brebi P.; Hoffstetter R; Andana, A; Ili CG; Saavedra, K; Viscarra, T; Retamal J.; Sanchez R.; Roa, JC

Abstract

Context: Aberrant hypermethylation of promoter region of tumor suppressor genes could be used as cancer biomarkers. Objective: To test methylation status of ZAR1 and SFRP4 promoter regions as potentials biomarkers for diagnosis of preneoplastic and neoplastic lesions of cervix. Materials and methods: Cytobrush samples were evaluated by Methylation specific PCR (MSP) and quantitative MSP (qMSP). Results: ZAR1 and SFRP4 methylation frequency increased as the grade of lesion increased and the differences between normal and cervical cancer (CC) are statistically significant (p<0.0001). qMSP showed higher ZAR1 and SFRP4 methylation levels in cancer than normal epithelia (p<0.001) and preneoplastics lesions (p<0.01). Discussion: qMSP quantify methylation levels and have high sensitivity and specificity. Conclusion: ZAR1 and SFRP4 qMSP could be used as potential biomarker for CC diagnosis.

Más información

Título según WOS: Evaluation of ZAR1 and SFRP4 methylation status as potentials biomarkers for diagnosis in cervical cancer: exploratory study phase I
Título según SCOPUS: Evaluation of ZAR1 and SFRP4 methylation status as potentials biomarkers for diagnosis in cervical cancer: Exploratory study phase i
Título de la Revista: BIOMARKERS
Volumen: 19
Número: 3
Editorial: TAYLOR & FRANCIS LTD
Fecha de publicación: 2014
Página de inicio: 181
Página final: 188
Idioma: English
DOI:

10.3109/1354750X.2013.867535

Notas: ISI, SCOPUS